Overview

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

Phase:

Phase 2

Details

Lead Sponsor:

Australasian Gastro-Intestinal Trials Group

Collaborator:

Olivia Newton-John Cancer Research Institute

Treatments:

Cetuximab
Panitumumab
Valproic Acid